Φορτώνει......
Factor VIII replacement is still the standard of care in haemophilia A
Prophylactic factor VIII (FVIII) has dramatically improved haemophilia A treatment, preventing joint bleeding and halting the deterioration of joint status. FVIII products with an extended plasma half-life further improve patients’ quality of life and increase therapeutic adherence. New licensed cla...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Blood Transfus |
|---|---|
| Κύριοι συγγραφείς: | , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Edizioni SIMTI - SIMTI Servizi Srl
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6917528/ https://ncbi.nlm.nih.gov/pubmed/31846611 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2450/2019.0211-19 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|